Human IL-1β ELISA Set
Product Specifications
- Catalogue N°
- 851.610.001 - 1 x 96 Discovery
851.610.005 - 5 x 96
851.610.010 - 10 x 96
851.610.015 - 15 x 96
851.610.020 - 20 x 96 - Assay Range
- 15.6 pg/ml - 500 pg/ml
- Sensitivity
- 5 pg/ml
- Target species
- Human
- Specificity
- Recognizes both natural (pro and mature) and recombinant human IL-1b
- Incubation
- From sample to end 3h45
- Sample Type
- Serum, Plasma, Cell culture supernatant
- Sample Size
- 100 µl
- Cross Reaction
- No cross reactivity with other human cytokines
- Kit Content
- Diaclone ELISA Sets include capture and biotinylated detection antibody, one standard per plate, Streptavidin-HRP, TMB, and detailed procedure including buffer composition.
- Synonym
- IL-1b
- IL-1beta
References
- Celik, B. et al.,Biomed Rep.,2016; 5(2): 259-263. - Pubmed link
- Haller D. et al., Clin. Diagn. Lab. Immunol., 2002; 9(3): 649 - 657 - Pubmed link
- Kankkunen, P. et al., J. Immunol., 2010; 184(11): 6335-6342 - Pubmed link
- Kankkunen, P. et al., J. Immunol.,2009; 182(10): 6418-6425 - Pubmed link
- Miettinen, J. J. et al., J. Virol.,2012;86:12770-12778 - Pubmed link
- Monga, N. et al.,Prog Orthod.2014;15(1):30 - Pubmed link
- Mörs, K. et al.,Croat Med J. 2018 Apr 30;59(2):46-55. - Pubmed link
- Rintahaka, J. et al., J. Immunol.,2008; 180(3): 1749-1757 - Pubmed link
- Valimaki, E. et al., Cell. Proteomics,2013; 12(3): 749-763 - Pubmed link
- Valimaki, E., et al., J. Immunol.,2016;197(8):3315-3325 - Pubmed link
- Fernández-Prior, Á. et al., Foods. 2021 Feb; 10(2): 227. - Pubmed link
- Kordulewska, N. K. et al., Nutrients. 2021 Jan; 13(1): 123. - Pubmed link
- Kordulewska, N.K. et al., Int J Mol Sci. 2021 Dec; 22(24): 13634. - Pubmed link
- Kordulewska, N. et al., J Inflamm Res. 2022; 15: 1501–1519. - Pubmed link
Related products
- 855.010.000 - Anti-Human IL-1β Azide Free
- 855.012.019 - Anti-Human IL-1β PE Conjugated
- 670.040.096 - Rat IL-1β ELISA Kit
- 850.006.048 - Human IL-1β ELISA Kit
- 856.101.001 - Human IL-1β ELISpot Set
- 856.101.001PC - Human IL-1β ELISpot Kit
- 869.100.010 - Human IL-1β ELISpot Pair
- 858.000.005 - Accessory Pack for ELISA set
- 857.260.000 - Anti-Human IL-1β Azide Free
BACKGROUND
Interleukin-1 Beta (IL-1b) is a member of the interleukin-1 family. This family consists of three structures related polypeptides. The first two are IL-1a and IL-1b, each of which has a broad spectrum of both beneficial and harmful biologic actions, and the third is IL-1-receptor antagonist, which inhibits the activities of interleukin-1.
IL-1 a and b present approximately 25% homology at the amino acid level, but the difference is in their tri dimensional structure. Two distinct receptor types have been isolated, that bind both forms.IL-1b are synthesized as a larger precursor, with a molecular weight 31kda. The molecular weight of the mature form is 17.5kDa.Unlike IL1a, the IL-1b precursor show a little or no biological activity in comparison to the mature form.
IL-1 is primarily an inflammatory cytokine. It belongs to a groups of cytokines with overlapping biologic properties (TNFa and IL-6). IL-1, TNF and IL-6 share the ability to stimulate T and B lymphocytes, increase cell proliferation, and initiate or suppress gene expression for several proteins. It exerts their effects by binding to specific receptors.
IL-1 (a and b) have similar biological properties, among them, the ability to induce fever, sleep, anorexia and hypotension. IL-1 stimulates the release of pituitary hormones, increases the synthesis of collagenases, resulting in the destruction of cartilage, and stimulates the production of prostaglandins, leading to decrease in the pain threshold. In addition IL-1 has some host-defense properties. However, whereas IL-1b is a secreted cytokine, IL-1a is predominantly a cell-associated cytokine.
IL-1 has also been implicated in the destruction of beta cells of the islets of Langerhans, the growth of myelogenous leukaemia cells, and the development of atherosclerotic plaques. It is described in several diseases : sepsis syndrome, rheumatoid arthritis, inflammatory Bowel disease, acute and chronic myelogenous leukaemia, insulino-dependant diabetes mellitus, artherosclerosis.
Version 19 - 09.22
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.